CADTH Canadian drug expert committee recommendation (final): Certolizumab pegol (Cimzia -- UCB Canada Inc.) indication : treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy
The CADTH Canadian Drug Expert Committee (CDEC) recommends that certolizumab pegol (CZP) be reimbursed for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy if certain conditions are met
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
November 2019, 2019
|
Edition: | Version: 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that certolizumab pegol (CZP) be reimbursed for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy if certain conditions are met |
---|---|
Physical Description: | 1 PDF file (10 pages) |